Cytokinetics Executive Sells Stock After Exercising Options; Company Reports Major Drug Launch and Capital Raises
Executive Vice President Andrew Callos sold a total value of $1.11 million in Cytokinetics common stock after utilizing exercised options. This transaction occurred against a backdrop of significant corporate activity for the company, including the German market entry of its heart drug Myqorzo and multiple large-scale capital offerings.